Softgel capsules offer unique advantages in oncology treatment, from enhancing drug delivery to improving patient compliance. Their rapid-release properties and the ability to incorporate self-emulsifying drug delivery systems (SEDDS) support precise dosing of high-potency oncology drugs. Softgel technology for oncology treatments also improves bioavailability and stability, making it a viable option for effective cancer therapy.
Meeting the unique needs of oncology treatment
Softgels comprise a gelatinous outer shell that encapsulates a liquid or semi-solid fill containing an active pharmaceutical ingredient (API). While this composition may seem straight forward, this dosage form offers numerous advantages that enhance both drug delivery and patient compliance, making it a versatile and useful dosage form option in modern pharmaceutical development.
The immediate-release properties of softgels are valuable in addressing the challenges of high-potency drug delivery in oncology. The gelatin shell rapidly dissolves in the stomach, allowing its liquid or semi-solid fill to be released almost immediately into the gastrointestinal tract. This immediacy is crucial when delivering potent oncology drugs, as precise dosing and timely onset are important for maximizing drug efficacy.
Fergus Binnie, Formulation Development Team Leader at Douglas, notes the importance of the API formulation in the immediate-release profile of a softgel.
“At Douglas, our expertise in self-emulsifying drug delivery systems allows us to develop precise formulations that ensure even dispersion of the API within the softgel. This uniformity minimizes variability in drug concentration, leading to consistent absorption by the body and supporting accurate dosing for oncology patients.”
Fergus Binnie, Formulation Development Team Leader at Douglas
Other posts you may be interested in...
Articles
Beyond SOPs: Assessing quality of contract development and manufacturing organizations
Beatrijs Van Liedekerke, GM of Quality at Douglas CDMO, determines how to assess a CDMO’s ability to deliver on promises of quality.
Learn MoreArticles
CRO, CMO, and CDMO partnerships: A guide for pharma and biotech companies
Susan Lynch-Smith, Head of Business Development, Douglas CDMO, discusses the critical role that CRO, CMO and CDMO partnerships play in R&D and drug development.
Learn MoreArticles
The case for softgels: Addressing stability, shelf-life, and bioavailability issues in pharmaceutical formulation
Softgel formulations can often address the stability, shelf-life and bioavailability challenges encountered in the development of oral medicines but require specialist expertise to deliver …
Learn More